The Journal of Urology
Volume 182, Issue 2 , Pages 721-727 , August 2009

The bcl2 −938CC Genotype Has Poor Prognosis and Lower Survival in Renal Cancer

  • Hiroshi Hirata

      Affiliations

    • Department of Urology, San Francisco Veterans Affairs Medical Center and University of California-San Francisco, San Francisco, California
    • ,
  • Yuji Hinoda

      Affiliations

    • Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
    • ,
  • Koichi Nakajima

      Affiliations

    • Department of Urology, Toho University Faculty of Medicine, Tokyo, Japan
    • ,
  • Nobuyuki Kikuno

      Affiliations

    • Department of Urology, San Francisco Veterans Affairs Medical Center and University of California-San Francisco, San Francisco, California
    • ,
  • Yutaka Suehiro

      Affiliations

    • Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
    • ,
  • Z. Laura Tabatabai

      Affiliations

    • Department of Pathology, San Francisco Veterans Affairs Medical Center and University of California-San Francisco, San Francisco, California
    • ,
  • Nobuhisa Ishii

      Affiliations

    • Department of Urology, Toho University Faculty of Medicine, Tokyo, Japan
    • ,
  • Rajvir Dahiya

      Affiliations

    • Department of Urology, San Francisco Veterans Affairs Medical Center and University of California-San Francisco, San Francisco, California
    • Corresponding Author InformationCorrespondence: Urology Research Center (112F), Veterans Affairs Medical Center and University of California-San Francisco, 4150 Clement St., San Francisco, California 94121 (telephone: 415-750-6964; FAX: 415-750-6639)

Received 31 October 2008

References 

  1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin. 2004;50:7
  2. Eggener SE, Yossepowitch O, Pettus JA, et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006;24:3101
  3. Kudo-Saito C, Wansley EK, Gruys ME, et al. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2. Clin Cancer Res. 2007;13:1936
  4. Chowdhury S, Larkin JM, Gore ME. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer. 2008;44:2152
  5. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 2006;13:1351
  6. Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2002;16:1045
  7. Stackhouse GB, Sesterhenn IA, Bauer JJ, et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol. 1999;162:2040
  8. Bilim V, Tomita Y, Kawasaki T, et al. Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer. J Natl Cancer Inst. 1996;88:686
  9. Ofner D, Riehemann K, Maier H, et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer. 1995;72:981
  10. Zhang GJ, Kimijima I, Tsuchiya A, et al. The role of bcl-2 expression in breast carcinoma (review). Oncol Rep. 1998;5:1211
  11. Silvestrini R, Benini E, Veneroni S, et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol. 1996;14:1604
  12. Fontanini G, Vignati S, Bigini D, et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995;71:1003
  13. Kallio JP, Hirvikoski P, Helin H, et al. Renal cell carcinoma MIB-1, Bax and Bcl-2 expression and prognosis. J Urol. 2004;172:2158
  14. Itoi T, Yamana K, Bilim V, et al. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer. 2004;90:200
  15. Seto M, Jaeger U, Hockett RD, et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-lg fusion gene in lymphoma. EMBO J. 1988;7:123
  16. Nückel H, Frey UH, Bau M, et al. Association of a novel regulatory polymorphism (−938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood. 2007;109:290
  17. Tanaka Y, Hirata H, Chen Z, et al. Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:92
  18. Bachmann HS, Otterbach F, Callies R, et al. The AA genotype of the regulatory BCL2 promoter polymorphism (−938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res. 2007;13:5790
  19. Sinicrope FA, Hart J, Michelassi F, et al. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1995;1:1103
  20. Winter JN, Andersen J, Reed JC, et al. BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. Blood. 1998;91:1391
  21. Zhang X, Takenaka I. Cell proliferation and apoptosis with BCL-2 expression in renal cell carcinoma. Urology. 2000;56:510
  22. Huang DC, O'Reilly LA, Strasser A, et al. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J. 1997;16:4628
  23. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009;59:42
  24. Dai Z, Papp AC, Wang D, et al. Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics. 2008;1:24
  25. Bandrés E, Zárate R, Ramirez N, et al. Pharmacogenomics in colorectal cancer: the first step for individualized-therapy. World J Gastroenterol. 2007;13:5888

 Study received Shimane Medical University and Toho University approval.

 Supported by National Institutes of Health Grants RO1CA101844, R01CA111470 and T32-DK07790, a Veterans Affairs REAP award, Merit Review grants and the Yamada Science Foundation.

PII: S0022-5347(09)00881-7

doi: 10.1016/j.juro.2009.03.081

The Journal of Urology
Volume 182, Issue 2 , Pages 721-727 , August 2009

Article Tools

* Image Usage & Resolution